Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

Mas, Sergi; Julià, Laura; Cuesta, Manuel J.; Crespo-Facorro, Benedicto; Vázquez-Bourgon, Javier; Spuch, Carlos; González-Pinto, Ana; Ibáñez, Ángela; Usall, Judith; Romero-López-Alberca, Cristina; Catalan, Ana; Mané Santacana, Anna; Bernardo, Miquel

doi:http://dx.doi.org/10.3389/fpsyt.2024.1497565

Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol

License

Citation

Mas S, Julià L, Cuesta MJ, Crespo-Facorro B, Vázquez-Bourgon J, Spuch C, Gonzalez-Pinto A, Ibañez A, Usall J, Romero-López-Alberca C, Catalan A, Mané A, Bernardo M. Applied pharmacogenetics to predict response to treatment of first psychotic episode: study protocol. Front Psychiatry. 2025;15:1497565. DOI: 10.3389/fpsyt.2024.1497565

Abstract

The application of personalized medicine in patients with first-episode psychosis (FEP) requires tools for classifying patients according to their response to treatment, considering both treatment efficacy and toxicity. However, several limitations have hindered its translation into clinical practice. Here, we describe the rationale, aims and methodology of Applied Pharmacogenetics to Predict Response to Treatment of First Psychotic Episode (the FarmaPRED-PEP project), which aims to develop and validate predictive algorithms to classify FEP patients according to their response to antipsychotics, thereby allowing the most appropriate treatment strategy to be selected. These predictors will integrate, through machine learning techniques, pharmacogenetic (measured as polygenic risk scores) and epigenetic data together with clinical, sociodemographic, environmental, and neuroanatomical data. To do this, the FarmaPRED-PEP project will use data from two already recruited cohorts: the PEPS cohort from the "Genotype-Phenotype Interaction and Environment. Application to a Predictive Model in First Psychotic Episodes" study (the PEPs study from the Spanish abbreviation) (N=335) and the PAFIP cohort from "Clinical Program on Early Phases of Psychosis" (PAFIP from the Spanish abbreviation) (N = 350). These cohorts will be used to create the predictor, which will then be validated in a new cohort, the FarmaPRED cohort (N = 300). The FarmaPRED-PEP project has been designed to overcome several of the limitations identified in pharmacogenetic studies in psychiatry: (1) the sample size; (2) the phenotype heterogeneity and its definition; (3) the complexity of the phenotype and (4) the gender perspective. The global reach of the FarmaPRED-PEP project is to facilitate the effective deployment of precision medicine in national health systems.